Skip to main content

AMERI Holdings Amalgamation Partner Jay Pharma Reports IRB Approval For Testing Proprietary CBD Formulation In Brain Cancer

Final approval is anticipated in summer 2020 to initiate phase I/II study in Glioblastoma Multiforme. The study will enroll 40 patients with recurrent or progressive GBM tumors who are currently undergoing chemotherapy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.